Study | Exclusion reasons | Rmk | Reference |
---|---|---|---|
Viktil (men), 2012 | other reason | EXCLUDED: Data related to paternal exposure. |
Viktil KK Scand J Rheumatol 2012;41:196-201 10.3109/03009742.2011.626442 |
Viktil (men), 2009 | other reason | EXCLUDED: Data related to paternal exposure. |
Viktil KK Pharmacoepidemiol Drug Saf 2009;18:737-42 10.1002/pds.1775 |
Viktil (women), 2012 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: Analysis performed on anti-rheumatic drugs as a whole, no individual analyse for each substance. Raw data (number of exposed pregnancies and malformations) were available for were provided in the text and were used for this meta-analysis. |
Viktil KK Scand J Rheumatol 2012;41:196-201 10.3109/03009742.2011.626442 |
Drechsel, 2020 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis according to DMARD as a whole, with specific data only for TNF and Etanercept but not for other treatments. |
Drechsel Rheumatology (Oxford) 2020; 59:603-612 10.1093/rheumatology/kez309 |
Viktil (women), 2009 | pattern of exposure | EXCLUDED: Pattern of exposure without data on fetal/maternal/neonatal safety outcomes. |
Viktil KK Pharmacoepidemiol Drug Saf 2009;18:737-42 10.1002/pds.1775 |